ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO1768

Burden of Illness of Lupus Nephritis in Patients with Systemic Lupus Erythematosus

Session Information

Category: Glomerular Diseases

  • 1202 Glomerular Diseases: Immunology and Inflammation


  • Bell, Christopher F., GlaxoSmithKline, Research Triangle, North Carolina, United States
  • Wu, Benjamin, GlaxoSmithKline, Research Triangle, North Carolina, United States
  • Xie, Bin, Optum, Eden Prairie, Minnesota, United States
  • Huang, Shirley, GlaxoSmithKline, Research Triangle, North Carolina, United States
  • Chastek, Benjamin, Optum, Eden Prairie, Minnesota, United States
  • Rubin, Bernie, GlaxoSmithKline, Philadelphia, Pennsylvania, United States
  • Von Feldt, Joan, GlaxoSmithKline, Philadelphia, Pennsylvania, United States
  • Bryant, Gary, GlaxoSmithKline, Philadelphia, Pennsylvania, United States

Approximately 35% of adults with systemic lupus erythematosus (SLE) develop lupus nephritis (LN). LN is associated with an increased risk of renal failure, cardiovascular disease, and death. Little is known about healthcare resource utilization (HRU) or costs of care for patients with LN versus those without SLE.


This retrospective cohort study used Optum Research Database administrative claims data (GSK Study 213062). Patients with LN had ≥2 renal diagnosis codes during 08/01/2017–07/31/2018 and ≥1 inpatient or ≥2 outpatient SLE diagnosis codes >30 days apart in the 12 months prior to index; index date was the date of first renal diagnosis code. The control cohort had plan members with no diagnosis codes for SLE or LN during 08/01/2016–7/31/2018. Control patients were matched 1:1 to patients with LN based on baseline demographics. Inclusion criteria: ≥18 years of age at index, and continuous medical and pharmacy coverage in the 12 months pre and post index. HRU in the 12 months post index captured ambulatory visits, emergency department (ED) visits, and hospitalizations. Total healthcare costs in the 12 months post-index were quantified combining health plan– and patient-paid amounts and adjusted using the Consumer Price Index.


Across the LN and control cohorts, 2326 patients met study criteria; 38.5% were 45–64 years of age, 44.1% were ≥65 years of age, 85.6% were female, 58.1% were located in Southern USA states, and 66.3% were covered by Medicare. The LN cohort had a significantly higher mean (standard deviation [SD]) number of ambulatory visits (53.93 [55.34] vs 18.27 [21.61]), ED visits (2.87 [7.91] vs 0.86 [2.31]), and hospitalizations (0.86 [1.48] vs 0.12 [0.51]) versus the control cohort, respectively. Mean (SD) total costs were $50,958 ($86,100) for the LN cohort, which were significantly higher than $10,737 ($21,741) in the control cohort. Differences in cost were largely driven by mean (SD) medical expenses for the LN cohort versus the control cohort ($40,648 [$78,134] vs $6,781 [$14,773] respectively). All p-values were <0.001.


All-cause HRU and costs were higher for patients with LN than patients without SLE. This study quantifies the economic burden associated with LN.


  • Commercial Support